Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the safety, tolerability, single-ascending dose (SAD), multiple-ascending dose (MAD), food effect, and pharmacokinetic (PK) Study of TML-6.
Interventions
DRUGTML-6 Granules
Administered orally
DRUGPlacebo
Administered orally
Sponsors
Merry Life Biomedical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy adults: Subject's age is ≥18 years old and ≤55 years old at screening Healthy elderly adults: Subject's age is ≥60 years old and ≤80 years old at screening Inclusion Criteria: 1. Healthy male and female volunteers 2. For Parts 1, 2, and 4 (Cohorts 1-5 and 7-8): Subject's age is ≥18 years old and ≤55 years old at screening. For Parts 3 and 5 (Cohorts 6 and 9): Subject's age is ≥60 years old and ≤80 years old at screening. 3. For Parts 1, 2, and 4 (Cohorts 1-5 and 7-8): Subjects whose body mass index (BMI) at screening is within a range of ≥18.5 kg/m2 and \<30.0 kg/m2 For Parts 3 and 5 (Cohorts 6 and 9): Subjects whose BMI \<30.0 kg/m2 Note: BMI = Body weight (kg) / \[Height (m)\]2; Body weight is not less than 50 kg at screening and admission. 4. Subjects who are deemed to be satisfactory health by the investigator through an assessment of their medical history, physical examinations, and routine laboratory tests. 5. Female subjects of child-bearing potential show negative pregnancy test results at screening and admission. 6. Female subjects of child-bearing potential, committing to practicing sexual abstinence or using and continue to use 2 highly effective contraceptives of birth control for at least 30 days prior to screening (that period will extend to 90 days for oral contraceptive use) and for at least 30 days after the last dose of investigational product (IP). For a subject to be considered not to be of child-bearing potential, she must have been amenorrheic for at least 12 months with confirmed follicle-stimulating hormone (FSH) level (within postmenopausal range) at screening, or must have had a hysterectomy, a bilateral tubal ligation, and/or a bilateral oophorectomy (as determined by the medical history). The male partner of a female study subject with childbearing potential must use a condom and ensure that his partner uses a highly effective contraception as outlined below. The highly effective contraception methods include: 1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment. 3. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject. 4. Combination of the following listed methods (d.1+d.2): d.1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception, intrauterine device (IUD), or intrauterine system (IUS). d.2. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps). 7. Subjects must demonstrate willingness to comply with all requirements, instructions and restrictions stated in the protocol, and must provide the written informed consent form after thorough understanding. \-
Exclusion criteria
1. Subjects with any properly diagnosed disease within 30 days prior to the first dose of the IP. 2. Subjects who have a QTcF interval \>450 msec (male) or \>470 msec (female) (Fridericia's correction) at screening. The assessment may be repeated once during the screening period. 3. Systolic blood pressure (SBP) \>140 mmHg or diastolic blood pressure (DBP) \>90 mmHg at screening and admission, irrespective of anti-hypertensive medication status for the subject. The assessments may be repeated for confirmation after resting for approximately 10 to 30 minutes. 4. Any laboratory values with the following deviations at screening and admission. The laboratory test may be repeated once during the screening period and Day -1. • White blood cell count (WBC) \< 3000/μL * Hemoglobin \< 10 g/dL * Platelet count \< 100000/μL * Creatinine \> upper limit of normal (ULN) * Alanine Aminotransferase (ALT) \> ULN * Aspartate Aminotransferase (AST) \> ULN * Total bilirubin \> ULN of the reference range \* If agreement is obtained per the investigator's discretion, exceptions may be made for isolated ALT or AST elevation \<1.5× ULN and bilirubin values that are above the ULN for subject has an underlying diagnosis of Gilbert's syndrome. 5. Subjects who have been tested positive for the following tests: \- Human immunodeficiency virus (HIV) \- Hepatitis B virus (HBV) \- Hepatitis C virus (HCV) 6. Female subjects who are lactating or with a positive pregnancy test at the screening visit and/or admission. 7. Subjects had a history of substance use disorders according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V) criteria. 8. Subjects with positive urine drug test (including cotinine detection) or positive blood alcohol test at screening and on Day -1 (and on Day 15+ in Cohort 2). 9. Subjects with underlying medical, mental, or psychological conditions that may impede study compliance, or, at the discretion of the investigator, preclude participation in the study. 10. The medical history indicates contraindications or hypersensitivity to the use of test medications \[TML-6 or any components of the IP\]. 11. Subjects took any of the following systemically-absorbed medications in the specified durations: \- Any medications (excluding vitamins, food supplements, and hormonal contraceptives for birth control) within 14 days prior to the first dose of the IP, unless in the opinion of the investigator and sponsor, the medication will not interfere with the study or compromise subject's safety. \- Any known enzyme inducers/inhibitors or agents that significantly alter hepatic or renal clearance (e.g., erythromycin, cimetidine, barbiturates, phenothiazine, clarithromycin, troleandomycin, ketoconazole, miconazole, fluconazole, itraconazole) within 30 days prior to the first dose of the IP. 12. Subjects had participated in investigational drug trials and took any investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the first dose of the IP. 13. Subjects had blood loss or blood donation of more than 250 and 500 mL within 60 and 90 days, respectively prior to the first dose of the IP. 14. Subjects who cannot stop caffeine-intake for 48 hours prior to the first study dose and during the entire study period. 15. Subjects who are smokers or former smokers who have used nicotine-containing products within 3 months prior to the first dose of the IP. 16. Unwilling or unable to comply with the lifestyle instructions described in the protocol. 17. Subjects appears to have poor venous access. 18. Subjects have any other condition which, in the opinion of the investigator, precludes the subject's participation in the study. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability: Incidence of Serious Adverse Events (SAEs) and treatment-related adverse events | All subjects at each dose level complete the 3-day safety assessments post-dose for part 1-3 study and all subjects at each dose level complete the 8-day safety assessments post the first dose for part 4 & 5 study | Incidence of SAEs and treatment-related severe AEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma PK: Maximum Plasma Concentration (Cmax) will be assessed for part 1-5 study | Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, and 48 hours postdose | Part 1-5 study (plasma PK): • Peak plasma concentration (PCmax,) \[ng/mL\] of TML-6 Part 2 only: Comparative bioavailability analysis in the extent of the peak concentration (PCmax)\[ng/mL\] of TML-6 under fed or fasting condition |
| Plasma PK: Area Under the Curve (AUC) will be assessed for part 1-5 study | Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, and 48 hours postdose | Part 1-5 study (plasma PK): The TML-6 plasma concentration-time profile will be established and Area under the concentration-time curve (AUC0→24, AUC0→last, 0→inf, and %AUCextrap)\[ng\*h/mL\] of TML-6 Part 2 only: Comparative bioavailability analysis in the extent of total exposure by area under the curve (AUC0→last and AUC0→inf) \[ng\*h/mL\] of TML-6 under fed or fasting condition |
| Plasma PK: Time to reach peak plasma concentration (Tmax) will be assessed for part 1-5 study | Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, and 48 hours postdose | Part 1-5 study (plasma PK): • Time to reach peak plasma concentration (Tmax)\[hours, or h\] of TML-6 Part 2 only: Comparative bioavailability analysis in the extent of the Time to reach peak concentration (Tmax)\[hours, or h\] of TML-6 under fed or fasting condition |
| Plasma PK: Terminal half-life (T1/2) will be assessed for part 1-5 study | Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, and 48 hours postdose | Part 1-5 study (plasma PK): • Terminal half-life (T1/2) \[hour\] of TML-6 Part 2 only: Comparative bioavailability analysis in the extent of Terminal half-life (T1/2) \[hour\] of TML-6 under fed or fasting condition |
| Plasma PK: Peak plasma concentration at steady state (Cmax,ss) will be assessed for part 4 and 5 study | predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose; Day 3: predose; Day 4:predose; Day 5:predose; Day 6: predose; Day7: predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose | Part 4-5 study (plasma PK): • Peak plasma concentration at steady state (Cmax,ss)\[ng/mL\] of TML-6 |
| Plasma PK: Area under the concentration-time curve (AUC0→24,ss and AUC0→τ,ss) will be assessed for part 4 and 5 study | predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose; Day 3: predose; Day 4:predose; Day 5:predose; Day 6: predose; Day7: predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose | Part 4-5 study (plasma PK): • Area under the concentration-time curve at steady state (AUC0→24,ss and AUC0→τ,ss) \[ng\*h/mL\] of TML-6 |
| Plasma PK: Terminal half-life at steady state (T1/2,ss) will be assessed for part 4 and 5 study | predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose; Day 3: predose; Day 4:predose; Day 5:predose; Day 6: predose; Day7: predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose | Part 4-5 study (plasma PK): • Terminal half-life at steady state (T1/2,ss) \[hour\] of TML-6 |
| Plasma PK: Accumulation ration (Rac) will be assessed for part 4 and 5 study | predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose; Day 3: predose; Day 4:predose; Day 5:predose; Day 6: predose; Day7: predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose | Part 4-5 study (plasma PK): • Accumulation ration (Rac) \[unit of ratio\] of TML-6 |
| CSF PK: Maximum observed concentration in CSF at steady state (CSF Cmax,ss) will be assessed for part 5 study | on Day 7 (prior to dosing, 0.5, 1, 2, 4, 8, 12, 16 hours after dosing) and Day 8 (24 hours after dosing) | CSF PK at steady-state (after the final dose) • Maximum observed concentration in CSF at steady state (CSF Cmax,ss)\[ng/mL\] of TML-6 |
| CSF PK: Time to reach peak concentration in CSF at steady state (Tmax,ss) will be assessed for part 5 study | on Day 7 (prior to dosing, 0.5, 1, 2, 4, 8, 12, 16 hours after dosing) and Day 8 (24 hours after dosing) | CSF PK at steady-state (after the final dose), • Time to reach peak concentration in CSF at steady state (Tmax,ss) \[hours, or h\] of TML-6 |
| CSF PK: Area under the CSF concentration-time curve from 0 to the 24 hours at steady state (CSF AUC0→24,ss) will be assessed for 5 study, if applicable | on Day 7 (prior to dosing, 0.5, 1, 2, 4, 8, 12, 16 hours after dosing) and Day 8 (24 hours after dosing) | CSF PK at steady-state (after the final dose), • Area under the CSF concentration-time curve from 0 to the 24 hours at steady state (CSF AUC0→24,ss)\[ng\*h/mL\] of TML-6, if applicable |
| CSF PK: Ratio of CSF AUC0→24,ss to Plasma AUC0→24,ss for part 5 study, if applicable | on Day 7 (prior to dosing, 0.5, 1, 2, 4, 8, 12, 16 hours after dosing) and Day 8 (24 hours after dosing) | • Ratio of CSF AUC0→24,ss to Plasma AUC0→24,ss\[unit of ratio\] of TML-6, if applicable |
| Plasma PK: Time to reach peak concentration at steady state (Tmax,ss) will be assessed for part 4 and 5 study | predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose; Day 3: predose; Day 4:predose; Day 5:predose; Day 6: predose; Day7: predose, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours postdose | Part 4-5 study (plasma PK): • Time to reach peak concentration at steady state (Tmax,ss) \[hours, or h\] of TML-6 |
Countries
United States
Outcome results
None listed